Samsung Biologics is buying more than GLP-1 capacity in its CHF 1.46bn PolyPeptide bet
Samsung Biologics’ CHF 1.46 billion PolyPeptide bid adds GLP-1 capacity and six global sites. Read why integration will decide its real long-term payoff.
Pharma & Biotech
Pharma & Biotech
Why Cartography Biosciences’ Phase 1 colorectal cancer trial matters after Samsung Ventures backing
Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.